News

May 18, 2018May 18, 2018

Potential Parkinson’s Vaccine, Affitope PD01A, Safe and Possibly Effective in Long-term, Phase 1 Trial Series Finds

News

Affiris’ experimental Parkinson’s vaccine, Affitope PD01A, is safe and effectively triggers an immune response against the alpha-synuclein (aSyn) protein, data from a series of four consecutive clinical trials show. Results from ... Read more

May 18, 2018May 18, 2018

How 2 Sets Nerve Cells Interact to Control Movement Seen by Scientists Using New Tool

News

Using a new tool, researchers were able to see how two different sets of neurons interact in mice to control movement. They believe the method, called spectrally resolved fiber ... Read more

May 17, 2018May 17, 2018

Affected Cell Type May Explain Differences in Parkinson’s-related Diseases, Study Suggests

News

Different brain cells determine which form of alpha-synuclein will be responsible for different Parkinson’s-related disorders, a new study suggests. The research, “Cellular milieu imparts distinct pathological α-synuclein strains in α-synucleinopathies,” was ... Read more

May 17, 2018May 17, 2018

Parkinson’s Researchers Unravel How Toxic Alfa-synuclein Affects Memory Nerve Cells

News

Scientists are closer to understanding how toxic alpha-synuclein (α-syn) aggregates affect the nerve cells involved in memory, which may point to new therapeutic strategies to prevent the development of ... Read more

May 16, 2018May 16, 2018

Enzyme Tied to Inflammation and Progression in Parkinson’s May Hold Key to Treatment, Study Says

News

Blocking an enzyme associated with inflammation and disease progression in Parkinson’s patients may by a promising way of treating this neurodegenerative disorder, new research suggests. The study, “Soluble epoxide ... Read more

May 16, 2018May 16, 2018

Alnylam’s RNAi Therapy for Parkinson’s Disease Fares Well in Rat Model

News

Alnylam’s small RNA interference (RNAi) therapies were delivered successfully to the brain and spinal cord of a rat model, bringing promise to the treatment of neurodegenerative diseases, including Parkinson’s. The company ... Read more

May 15, 2018May 15, 2018

Eli Lily Recruiting for Phase 2 Trial to Test LY3154207 for Parkinson’s Dementia

News

Eli Lilly is recruiting patients for its Phase 2 clinical trial evaluating LY3154207 as a potential treatment for Parkinson’s disease dementia (PDD). Parkinson’s disease destroys the nerve cells that ... Read more

May 15, 2018May 15, 2018

Charles River Laboratories, Michael J. Fox Foundation Extend Research Partnership

News

Charles River Laboratories International and The Michael J. Fox Foundation for Parkinson’s Research (MJFF) extended their collaboration to accelerate the discovery of Parkinson’s disease therapies. The extension covers grants from MJFF ... Read more

May 14, 2018May 14, 2018

Dance-movement Therapy May Help Parkinson’s, Other Motor Diseases, Study Finds

News

New methods to measure brain activity in dancers can be applied to develop new forms of treatment, such as dance-movement therapy, for movement-related disorders including Parkinson’s disease, according to a Finnish ... Read more

May 14, 2018May 14, 2018

MJFF Partners with Verily to Use Data Collection Watch in PPMI Study to Advance Parkinson’s Research

News

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Verily Life Sciences are collaborating to collect data on movement, physiological, and environmental measures in Parkinson’s patients for the MJFF-led Parkinson’s ... Read more

Pin It on Pinterest